PHARMACOSMOS A/S

Legal ownership resolution (ejerforholdenes opløsning)

Ends at a personThe chain of majority owners ends at a person, through 5 companies; legal owners in the CVR owner register only. Dandex estimate, rule v3, computed 13 Nov 2026.

Control tenure (ejerskabsperiode)

Pro: Control tenure (ejerskabsperiode) is in the Pro plan, see pricingHow long the current ultimate controller has held control, from the CVR owner register.

Group position (koncernforhold)

Has a parent, and no majority holding in a Danish companyControlled by a company in CVR; it holds 50% or more of no Danish company. Dandex estimate, rule v2, computed 13 Nov 2026.

Signing authority, structured (tegningsregel, struktureret)

Not read: Dandex does not yet read rules worded this wayThe wording of the registered signing rule is not one the grammar reads; see the rule as registered. Dandex estimate, rule v2, computed 13 Nov 2026.

EU SME size class (SMV-kategori)

Large enterprise286 average employees, turnover EUR 291.7M, balance sheet EUR 609.1M in the 2026 report, and the same class the year before. Dandex estimate, rule v2, computed 13 Nov 2026.

Long-run headcount growth (beskæftigelsesudvikling siden 1998)

Growing fastEmployees +10.2% a year over 10 years to Aug 2026, from 117 to 308 on average; the peak was 320 in 2026. Dandex estimate, rule v1, computed 13 Nov 2026.

Demand cyclicality (konjunkturfølsomhed)

Pro: Demand cyclicality (konjunkturfølsomhed) is in the Pro plan, see pricingHow demand for its products moves with the economy, from its industry.

Registry and report headcount compared (ansatte i register og regnskab)

Pro: Registry and report headcount compared (ansatte i register og regnskab) is in the Pro plan, see pricingThe report's average employees beside the registry's staff over the same year.

Auditor's report (revisorpåtegning)

AuditTagged in the report (cmn:TypeOfAuditorAssistance). Dandex estimate, rules and decision model v1, computed 12 Nov 2026, from the annual report for the year ending 30 Apr 2026.

Auditor's report findings (revisorpåtegning)

Pro: Auditor's report findings (revisorpåtegning) is in the Pro plan, see pricingThe auditor's findings: conclusion, going concern, emphasis, other matters, breaches.

Business model (forretningsmodel)

Not determinedNot decided yet: Dandex has not read this company's annual reports for it. Dandex estimate, rules and decision model v1, computed 13 Nov 2026.

Revenue model (indtægtsmodel)

Pro: Revenue model (indtægtsmodel) is in the Pro plan, see pricingThe kinds of revenue the accounting policies name, and the main one.

Decided by Dandex with fixed rules from CVR and the filed annual reports, and for the auditor's report, the business model and the revenue model a calibrated decision model reading the report's text and the purpose clause, not registered by the company. Each label links to its definition.

DKK thousands. Annual reports via XBRL. Employees are the annual report's average and may cover a group.

Credit rating (kreditvurdering)

Pro: Credit rating (kreditvurdering) is in the Pro plan, see pricingA score from 0 to 100 with a grade from A to F, from the latest annual reports.

Capital loss (kapitaltab)

Pro: Capital loss (kapitaltab) is in the Pro plan, see pricingNegative equity, or equity below half the share capital, in the latest report.

Filing deadline and punctuality (indsendelsesfrist)

Pro: Filing deadline and punctuality (indsendelsesfrist) is in the Pro plan, see pricingThe next annual report deadline.

No changes since Dandex began following this company. For announcements from before then, see Registrations.

As read on 13 Nov 2026. Dandex could not read it again just now.

Pro for this company

The rows marked Pro on this page hold values in the Pro plan. For PHARMACOSMOS A/S, that is:

Credit and debt

Net interest-bearing debt, gearing, NIBD / EBITDA, interest coverage and adjusted equity ratio, for 2022 to 2026.Credit rating, capital loss and filing deadline and punctuality.

Returns and cash flow

ROIC, capex % of sales and FCFF / EBITDA, for 2022 to 2026.

Advanced estimates

Control tenure, demand cyclicality, registry and report headcount compared, auditor's report findings and revenue model.

Signals and monitoring

Signals on this company, as Dandex raises them.

See the Pro plan

Have Pro? Sign in to see the values on this page.

Signing rule (tegningsregel)

Selskabet tegnes af den samlede bestyrelse, eller af et medlem af direktionen og et medlem af bestyrelsen i forening, eller af Tobias Sidelmann Christensen.since 12 Jul 2022

Purpose (formål)

Selskabets formål er at drive fabrikation og virksomhed i forbindelse hermedsince 3 Nov 2010

Audit opted out (revision fravalgt)

Nosince 1 Oct 1991

Articles of association last changed (seneste vedtægtsdato)

28 Jun 2022

Share classes (kapitalklasser)

Yessince 10 Feb 1992

From CVR, read 13 Nov 2026. Text such as the signing rule and purpose is shown as registered.

Name changes

3 in all, none in the last 5 years; latest 29 Nov 2005

Address changes

1 in all, none in the last 5 years; latest 27 Feb 2004At the current address for 22.7 years

Status changes

None recorded

Auditor changes

3 in all, none in the last 5 years; latest 15 Sep 2008With the current audit firm for 18.2 years

From CVR, read 13 Nov 2026. A change is counted each time the registry records a new value, so a corrected address or an audit firm under a new entity counts too.

41 registrations, newest first. As published by Erhvervsstyrelsen, in Danish, with people's street addresses cut to postcode and city.

1. 23 Sep 2025
   People change

   Direktion:

   Tiltrådte:

   Claes Christian Strøm, den 18.09.2025.

2. 10 Jul 2024
   People change

   Bestyrelse:

   Fratrådte:

   Tommy Pedersen, den 27.06.2024.

   Tiltrådte:

   Lars Green, den 27.06.2024, Milena Jordanova Olsen, den 27.06.2024.

3. 14 Dec 2023
   People change

   Direktion:

   Fratrådte:

   Robert Guglielmetti, den 08.12.2023.

   Tiltrådte:

   Henrik Parker Mathisson, den 08.12.2023.

4. 17 Aug 2023
   People change

   Bestyrelse:

   Tiltrådte:

   Martin Holst Lange, den 15.08.2023.

5. 22 Jul 2022
   Other

   Navn og adresse:

   PHARMACOSMOS A/S Rørvangsvej 30, postboks 40, 4300 Holbæk

   Ny adresse:

   Rørvangsvej 30, 4300 Holbæk

6. 12 Jul 2022
   People change

   Vedtægter ændret: 28.06.2022

   Direktion:

   Fratrådte:

   Lars Christensen, (adm. dir), den 28.06.2022.

   Tiltrådte:

   Tobias Sidelmann Christensen, (adm. dir), den 28.06.2022.

   Selskabet tegnes af den samlede bestyrelse, eller af et medlem afdirektionen og et medlem af bestyrelsen i forening, eller af Tobias Sidelmann Christensen.

7. 17 May 2021
   Merger or demerger completed

   Erhvervsstyrelsen har modtaget oplysning om, at der er truffet beslutning om nedenstående spaltning.

   Aktiver og gæld er overdraget til CVR-nummer 42388084 Pharmacosmos Facilities ApS.

8. 13 Apr 2021
   Merger or demerger announced

   Erhvervsstyrelsen har modtaget spaltningsplan for den påtænkte spaltning af CVR-nummer: 15517085 PHARMACOSMOS A/S (indskydende fortsættende), der tillige driver virksomhed under navnene SOLOCHEM A/S, PHARMACOSMOS PHARMACEUTICALS A/S, NEBO A/S, NEBO INDUSTRIES A/S, NEBO PHARMACEUTICAL A/S, NEBO HOSPITAL PRODUCTS A/S, UNIVET A/S, SOLOVET A/S.

   De øvrige deltagende virksomheder er en/flere nye virksomheder.

   Erhvervsstyrelsen har modtaget erklæring fra vurderingsmændene om, at kreditorerne i CVR-nummer: 15517085 PHARMACOSMOS A/S må antages at være tilstrækkeligt sikrede efter spaltningen.

9. 6 Oct 2020
   Other

   Vedtægter ændret: 28.09.2020

   Selskabet tegnes af den samlede bestyrelse, eller af et medlem afdirektionen og et medlem af bestyrelsen i forening, eller af Lars Christensen.

10. 11 Feb 2019
    People change

    Bestyrelse:

    Fratrådte:

    Axel Kierkegaard, (formand), den 08.02.2019.

    Tiltrådte:

    Jacob Tolstrup, (formand), den 08.02.2019.